CodeMap® Compliance Briefing: March 4, 2016
Most new clinical applications of mass spectrometry are evolving without the benefit of appropriate reimbursement policy by Medicare and other commercial payers. At the same time, the overutilization of urine drug testing in pain management has resulted in draconian cuts to reimbursement for testing performed using traditional chromatography/mass spectrometry methods. These developments have placed providers that perform mass spectrometry in a difficult and uncertain place. The following briefing will discuss the coding and reimbursement issues that have recently developed concerning mass spectrometry
Sorry, the full document you are trying to access requires an active subscription.
Please login to the left.